Chief Endocrine Physician & Founder
Founder and Chairman - Rudraksha Institute of Medical Sciences
Dr. Vipul Chavda is a highly accomplished and respected Endocrine Physician with extensive experience in diabetic care, endocrinology, and internal medicine. As the Founder and Chairman of Rudraksha Institute of Medical Sciences, he is recognized for excellence in patient care, medical education, and contributions to the medical community through various leadership roles. He is adept at integrating evidence-based medical practices with patient-centered care and is a renowned speaker with a track record of engaging and informative presentations at national and international conferences.
Rudraksha Institute of Medical Sciences, Ahmedabad
Leading the institute in providing comprehensive endocrine and diabetes care, medical education, and clinical research.
Founder of the campaign to make initiation and titration of insulin easy for HCPs and people with Diabetes
Initiated campaign for advocacy and awareness regarding obesity
Member of the initiative for increasing awareness regarding Diabetes & Lifestyle disorders in Women
National Campaign to increase awareness for Diabetes
Improving the quality of lives of kids with Diabetes - DRIMS charitable trust
Empowering HCPs through education and team support
2019: Evaluate Efficacy and Safety of Metformin with / without Concomitant Administration of Thymoquinone in Patients with T2DM (Phase II) - Principal Investigator
2019-2020: Evaluate the Safety and Efficacy of USVCAP Formulation in T2DM (Phase II) - Principal Investigator
2021: START-AM- Acarbose/Metformin Fixed Dose Combination: Treatment patterns and Outcomes in Newly Diagnosed T2DM patients in India (Phase IV) - Principal Investigator
2021: Study Of Nimesulide And Paracetamol Combination In Acute Pain Management (Phase IV) - Principal Investigator
2022: Efficacy and safety of a fixed dose combination of Metformin, Sitagliptin 100 mg and Pioglitazone 15 mg tablets versus Janumet XR CP in patients with Type 2 Diabetes Mellitus (T2DM) (Phase III) - Co-Investigator
2023: TOPSPIN- Treatment Optimisation of Blood Pressure with Single pill combination for India (Phase IV) - Co-Investigator
2024: Study investigating clinical parameters associated with the initiation of once-daily oral semaglutide in a real-world adult population with type 2 diabetes in India (RWE) - Co-Investigator
Dariya SS, Maheshwari A, Viswanathan V, et al. Assessment of the Awareness of Risk Factors and Current Behavior Among Individuals With Type 2 Diabetes Mellitus in India: A Cross-Sectional Study. Cureus. 2025 Mar 13;17(3):e80512.
Kiru G, Roy A, Kondal D, et al. Treatment optimisation for blood pressure with single-pill combinations in India (TOPSPIN) - Protocol design and baseline characteristics. Int J Cardiol Cardiovasc Risk Prev. 2024 Oct 24;23:200346.
Saboo, B., Inamdar, A., Saboo, S., Hasnani, D., & Chavda, V. Managing childhood obesity: teleconsultation as good as routine care. Endocrine Abstracts. 2024 May; Vol. 99.
Saboo, B., Inamdar, A., Chavda, V., & Hasnani, D. Effect of Diabetes education through social media in young patients with type 1 diabetes. Endocrine Abstracts. 2024 May; Vol. 99.
Maheshwari, A., Tewari, A., & Chavda, V. 635-P: Impact of Vitamin D Supplementation on Insulin Resistance amongst People with Type 2 Diabetes in India. Diabetes. 2024;73(Supplement_1).
Hasnani, D., Jha, S., Saboo, B., Prasanna, P. L., Sanghvi, A., Sowani, A., & Chavda, V. Efficacy of Insulin Degludec/Insulin Aspart (IDegAsp) vs. Insulin Glargine (IGlarU300) in Insulin-Naïve Patients with Type 2 Diabetes: A Retrospective Study. Clinical Diabetology. 2024;1(1):67-75.
Prajapati, S., Suthar, J., Hasnani, D., & Chavda, V. Adverse Drugs Reaction and Prescribing Pattern of Antidiabetic Medications in Type 2 Diabetes Patients: An Observational Ambispective Study. Clinical Diabetology. 2024;13(3):170-179.
Hasnani, D., & Chavda, V. Navigating the Complex Management Landscape of Type 1 Diabetes in Clinical Practice. Clinical Diabetology. 2023;12(6):324-326.
Maheshwari, Anuj, Dhruvi Hasnani, Meenakshi Bhattacharya, et al. Assessment of determining factors for severity of NeoCOVIDiabetes in India: A pan India multicentric retrospective study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2023;17(1):102692.
Hasnani, Dhruvi, Bharat Saboo, Ashutosh Chaturvedi, et al. Current insulinization trends in India. International Journal of Diabetes in Developing Countries. 2023;43(3):363-370.
Chavda, Vipul, Santosh Jha, Tejal R. Gandhi, et al. The efficacy of Tadalafil and Tadalafil+ Dapoxetine in managing sexual dysfunction in individuals with type-2 diabetes mellitus: A clinical study. Journal of Diabetology. 2023;14(1):48-55.
Chavda, Vipul, Dhruvi Hasnani, Shriji Hasnani, et al. 1832-PUB: SECRET–Screening and Educating Adolescents for Obesity. Diabetes. 2023;72(Supplement_1).
Chavda, Vipul, Banshi D. Saboo, Vk Abhichandani, et al. 144-LB: Assessment of Drug Prescription Patterns of Patients with Type 2 Diabetes Mellitus in India. Diabetes. 2023;72(Supplement_1).
Saboo, Bharat, Shweta Saboo, Vipul Chavda, And Dhruvi Hasnani. 1063-P: Impact of Mobile Messaging on Follow-up and Glycemic Control in the Indian Population. Diabetes. 2023;72(Supplement_1).
Saboo, Bharat, Vipul Chavda, Aniket Inamdar, Ajoy Tewari, and Dhruvi Hasnani. Diabetes Distress among Type 1 Diabetic adolescents in India. Endocrine Abstracts. 2023; Vol. 90.
Vyas, Tarjani C., Banshi D. Saboo, Kaumudi Chennamsetti, et al. 382-P: Is Sulphonylurea-Induced Hypoglycaemia Hyped among Clinicians?. Diabetes. 2022;71(Supplement_1).
Tewari, Ajoy, Vineeta Tewari, Jay Tewari, Bharat Saboo, et al. 480-P: Correlation of Tg/HDL Ratio and Liver Fibrosis in People with Diabetes in a Tertiary Care Center in India. Diabetes. 2022;71(Supplement_1).
Hasnani, Dhruvi, Vipul Chavda, Dinesh Agrawal, et al. Validation of RSSDI therapeutic wheel with clinical experience of Indian physicians. International Journal of Diabetes in Developing Countries. 2022:1-8.
Hasnani, Dhruvi, and Vipul Chavda. Saroglitazar: One Molecule for Managing Two Diseases, Type 2 Diabetes and Hypertriglyceridemia. Clinical Diabetology. 2022;11(5):301-302.
Gokalani, Rutul, Dharmendra Panchal, Banshi Saboo, et al. The extent of use of SGLT2 inhibitors in patients with type 2 diabetes in clinical practice: A study from India. Journal of Diabetology. 2021;12(3):305-309.
Jaggi, Shalini, Rajeev Chawla, Dhruvi Hasnani, Vipul Chavda, et al. Abstract# 1004315: Evaluation of the Patient Perceptions towards the Cost of Diabetes Therapy During the COVID-19 Era. Endocrine Practice. 2021;27(6):S195.
Ali, Shoukath M., Paul Chen, Saifuddin Sheikh, et al. Thymoquinone with metformin decreases fasting, post prandial glucose, and HbA1c in type 2 diabetic patients. Drug Research. 2021;71(06):302-306.
Saboo, Bharat, Abhishek Shrivastav, Aniket Inamdar, et al. India epidemiological mapping study-attempt at early screening-early intervention. Endocrine Abstracts. 2022; Vol. 81.
Chavda, Vipul, Dhruvi Hasnani, Banshi D. Saboo, et al. 2138-PUB: Determining Early Stage CVD in Patients of T2DM Using Flow-Mediated Dilatation Score. Diabetes. 2020;69(Supplement_1).
Shah, Shivesh, Banshi D. Saboo, Shailin Shah, et al. 2230-PUB: A Portrait of HbA1c Levels amongst Adults Diagnosed with Diabetes Mellitus in Suburban Ahmedabad. Diabetes. 2020;69(Supplement_1).
Shah, Shivesh, Kranthi Prasad, Banshi D. Saboo, et al. 1186-P: Effectiveness of a Community-Based Approach Towards the Treatment and Prevention of Diabetes Mellitus in Rural India. Diabetes. 2020;69(Supplement_1).
Parekh, Malay, Banshi Saboo, Dharmendra Panchal, et al. To estimate the prevalence of obesity and abdominal obesity in adult patients. Endocrine Abstracts. 2020; Vol. 70.
Chudasama, Dipak B., Banshi D. Saboo, Dharmendra Panchal, et al. The efficacy of teneligliptin with metformin in Drug-Naïve type 2 subjects. Diabetes. 2018;67(Supplement_1).
Chavda, Vipul, Banshi Saboo, Shriji Hasnani, et al. A15456 Efficacy of Cilnidipin vs. Amlodipin on microalbuminuria in hypertensive patients-clinical experience. Journal of Hypertension. 2018;36:e232.
Kadri, Mahira, Dhruvi Hasnani, Feny Patel, et al. USE OF EMPAGLIFLOZIN AS A SECOND LINE AGENT e REAL LIFE EXPERIENCE. VASCULAR. 2018;4:011.
Hasnani, Dhruvi, and Vipul Chavda. Perioperative Management Using Insulin Therapy. RSSDI's Insulin Monograph: A Complete Guide to Insulin Therapy. 2020:292.
Ahmedabad, Gujarat, India
Email: drvpchavda@gmail.com
LinkedIn: www.linkedin.com/in/vipul-chavda-02a656158
For appointments and consultations, please contact the institute directly.